Awad A Ahmed1, Wei-Ting Hwang2, Emma B Holliday3, Christina H Chapman4, Reshma Jagsi4, Charles R Thomas5, Curtiland Deville6. 1. Sylvester Comprehensive Cancer Center University of Miami Health System, Miami, Florida. 2. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 5. Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. 6. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland. Electronic address: cdeville@jhmi.edu.
Abstract
PURPOSE: Our purpose was to assess comparative female representation trends for trainees and full-time faculty in the academic radiation oncology and hematology oncology workforce of the United States over 3 decades. METHODS AND MATERIALS: Simple linear regression models with year as the independent variable were used to determine changes in female percentage representation per year and associated 95% confidence intervals for trainees and full-time faculty in each specialty. RESULTS: Peak representation was 48.4% (801/1654) in 2013 for hematology oncology trainees, 39.0% (585/1499) in 2014 for hematology oncology full-time faculty, 34.8% (202/581) in 2007 for radiation oncology trainees, and 27.7% (439/1584) in 2015 for radiation oncology full-time faculty. Representation significantly increased for trainees and full-time faculty in both specialties at approximately 1% per year for hematology oncology trainees and full-time faculty and 0.3% per year for radiation oncology trainees and full-time faculty. Compared with radiation oncology, the rates were 3.84 and 2.94 times greater for hematology oncology trainees and full-time faculty, respectively. CONCLUSION: Despite increased female trainee and full-time faculty representation over time in the academic oncology physician workforce, radiation oncology is lagging behind hematology oncology, with trainees declining in recent years in radiation oncology; this suggests a de facto ceiling in female representation. Whether such issues as delayed or insufficient exposure, inadequate mentorship, or specialty competitiveness disparately affect female representation in radiation oncology compared to hematology oncology are underexplored and require continued investigation to ensure that the future oncologic physician workforce reflects the diversity of the population it serves.
PURPOSE: Our purpose was to assess comparative female representation trends for trainees and full-time faculty in the academic radiation oncology and hematology oncology workforce of the United States over 3 decades. METHODS AND MATERIALS: Simple linear regression models with year as the independent variable were used to determine changes in female percentage representation per year and associated 95% confidence intervals for trainees and full-time faculty in each specialty. RESULTS: Peak representation was 48.4% (801/1654) in 2013 for hematology oncology trainees, 39.0% (585/1499) in 2014 for hematology oncology full-time faculty, 34.8% (202/581) in 2007 for radiation oncology trainees, and 27.7% (439/1584) in 2015 for radiation oncology full-time faculty. Representation significantly increased for trainees and full-time faculty in both specialties at approximately 1% per year for hematology oncology trainees and full-time faculty and 0.3% per year for radiation oncology trainees and full-time faculty. Compared with radiation oncology, the rates were 3.84 and 2.94 times greater for hematology oncology trainees and full-time faculty, respectively. CONCLUSION: Despite increased female trainee and full-time faculty representation over time in the academic oncology physician workforce, radiation oncology is lagging behind hematology oncology, with trainees declining in recent years in radiation oncology; this suggests a de facto ceiling in female representation. Whether such issues as delayed or insufficient exposure, inadequate mentorship, or specialty competitiveness disparately affect female representation in radiation oncology compared to hematology oncology are underexplored and require continued investigation to ensure that the future oncologic physician workforce reflects the diversity of the population it serves.
Authors: Erqi L Pollom; Navjot Sandhu; Jessica Frank; Jacob A Miller; Jean-Pierre Obeid; Noah Kastelowitz; Neil Panjwani; Scott G Soltys; Hilary P Bagshaw; Sarah S Donaldson; Kathleen Horst; Beth M Beadle; Daniel T Chang; Iris Gibbs Journal: Adv Radiat Oncol Date: 2020-05-20
Authors: Curtiland Deville; Ian Cruickshank; Christina H Chapman; Wei-Ting Hwang; Rhea Wyse; Awad A Ahmed; Karen M Winkfield; Charles R Thomas; Iris C Gibbs Journal: Int J Radiat Oncol Biol Phys Date: 2020-07-12 Impact factor: 7.038
Authors: Awad A Ahmed; Stephen J Ramey; Mary K Dean; Stella K Yoo; Emma Holliday; Curtiland Deville; Cristiane Takita; Neha Vapiwala; Lynn D Wilson; Reshma Jagsi; Charles R Thomas; Raphael Yechieli Journal: Adv Radiat Oncol Date: 2018-03-20
Authors: Rana Salem; Yolla Haibe; Christelle Dagher; Charelle Salem; Ali Shamseddine; Nizar Bitar; Joseph Makdessi; Sami Khatib; Hamouda Boussen; Farouk Benna; Sana Al Sukhun; Nagi El Saghir; Sally Temraz; Deborah Mukherji Journal: ESMO Open Date: 2019-06-14
Authors: Gita Suneja; Malcolm D Mattes; Raymond B Mailhot Vega; Freddy E Escorcia; Colleen Lawton; Joel Greenberger; Aparna H Kesarwala; Alexander Spektor; Bhadrasain Vikram; Curtiland Deville; Malika Siker Journal: Adv Radiat Oncol Date: 2020-05-21
Authors: Bismarck Odei; Jenna Kahn; Emma Brey Holliday; Dayssy Alexandra Diaz; Erika Bello-Pardo; James Odei; Junu Bae; Andrea Arnett; Raju Raval; Darrion Mitchell Journal: Adv Radiat Oncol Date: 2021-06-04
Authors: Emma B Holliday; Malika Siker; Christina H Chapman; Reshma Jagsi; Danielle S Bitterman; Awad A Ahmed; Karen Winkfield; Maria Kelly; Nancy J Tarbell; Curtiland Deville Journal: Adv Radiat Oncol Date: 2018-10-21